Compare LVO & LONA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LVO | LONA |
|---|---|---|
| Founded | 2009 | 2011 |
| Country | United States | United States |
| Employees | N/A | 19 |
| Industry | Restaurants | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.7M | 76.8M |
| IPO Year | 2010 | N/A |
| Metric | LVO | LONA |
|---|---|---|
| Price | $6.08 | $8.35 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $11.50 | $10.00 |
| AVG Volume (30 Days) | ★ 63.0K | 18.8K |
| Earning Date | 06-17-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 78.57 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $114,405,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $23.04 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.43 | $4.21 |
| 52 Week High | $7.19 | $14.21 |
| Indicator | LVO | LONA |
|---|---|---|
| Relative Strength Index (RSI) | 49.60 | 43.52 |
| Support Level | $5.97 | $7.99 |
| Resistance Level | $7.10 | $9.62 |
| Average True Range (ATR) | 0.47 | 0.54 |
| MACD | -0.07 | -0.02 |
| Stochastic Oscillator | 14.49 | 37.46 |
LiveOne Inc, formerly LiveXLive Media Inc is a premium internet network devoted to live music and music-related video content. The company has been building an online destination for music fans to enjoy live performances from music venues and music festivals around the world, such as Rock in Rio, Outside Lands Music and Arts Festival, and Hangout Music Festival, as well as original content, artist exclusives, and industry interviews. The Company operates mainly through three segments, PodcastOne, Slacker, and Media Group, with a majority of its revenue derived from the Slacker segment.
LeonaBio Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for high unmet medical needs. Its key drug candidates, lasofoxifene and ATH-1105, are novel, small-molecule therapies with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). LeonaBio is also exploring the use of other drug candidates that enhance the neurotrophic HGF system, including ATH-1020, to improve neuronal health and function in multiple neurological diseases. In addition, it is also focused on designing and testing new early compounds directed towards novel targets for a variety of clinical applications. The company operates as a single operating segment, developing and commercializing therapeutics.